JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Price & Overview
NASDAQ:JAZZ • IE00B4Q5ZN47
Current stock price
The current stock price of JAZZ is 194.2 USD. Today JAZZ is down by -1.99%. In the past month the price increased by 7.7%. In the past year, price increased by 93.23%.
JAZZ Key Statistics
- Market Cap
- 11.955B
- P/E
- 23.68
- Fwd P/E
- 7.79
- EPS (TTM)
- 8.20
- Dividend Yield
- N/A
JAZZ Stock Performance
JAZZ Stock Chart
JAZZ Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to JAZZ. When comparing the yearly performance of all stocks, JAZZ is one of the better performing stocks in the market, outperforming 90.79% of all stocks.
JAZZ Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to JAZZ. JAZZ has a medium profitability rating, but doesn't score so well on its financial health evaluation.
JAZZ Earnings
On February 24, 2026 JAZZ reported an EPS of 6.64 and a revenue of 1.20B. The company missed EPS expectations (-0.11% surprise) and beat revenue expectations (0.75% surprise).
JAZZ Forecast & Estimates
23 analysts have analysed JAZZ and the average price target is 228.13 USD. This implies a price increase of 17.47% is expected in the next year compared to the current price of 194.2.
For the next year, analysts expect an EPS growth of 204.02% and a revenue growth 4.77% for JAZZ
JAZZ Groups
Sector & Classification
JAZZ Financial Highlights
Over the last trailing twelve months JAZZ reported a non-GAAP Earnings per Share(EPS) of 8.2. The EPS decreased by -61.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.05% | ||
| ROE | -8.25% | ||
| Debt/Equity | 1 |
JAZZ Ownership
JAZZ Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.88 | 901.088B | ||
| JNJ | JOHNSON & JOHNSON | 20.47 | 581.222B | ||
| MRK | MERCK & CO. INC. | 23.46 | 303.313B | ||
| PFE | PFIZER INC | 9.02 | 154.837B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.26 | 121.109B | ||
| ZTS | ZOETIS INC | 16.65 | 50.651B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.27 | 27.862B | ||
| VTRS | VIATRIS INC | 5.37 | 15.67B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.99 | 11.664B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.151B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.797B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.066B | ||
| CORT | CORCEPT THERAPEUTICS INC | 50.73 | 4.494B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About JAZZ
Company Profile
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 2,890 full-time employees. The company went IPO on 2012-01-18. The company is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Company Info
IPO: 2012-01-18
JAZZ PHARMACEUTICALS PLC
Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4
DUBLIN DUBLIN D04 IE
CEO: Bruce C. Cozadd
Employees: 2800
Phone: 35316347800
JAZZ PHARMACEUTICALS PLC / JAZZ FAQ
Can you describe the business of JAZZ PHARMACEUTICALS PLC?
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 2,890 full-time employees. The company went IPO on 2012-01-18. The company is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Can you provide the latest stock price for JAZZ PHARMACEUTICALS PLC?
The current stock price of JAZZ is 194.2 USD. The price decreased by -1.99% in the last trading session.
Does JAZZ stock pay dividends?
JAZZ does not pay a dividend.
What is the ChartMill technical and fundamental rating of JAZZ stock?
JAZZ has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the analyst forecast for JAZZ stock?
23 analysts have analysed JAZZ and the average price target is 228.13 USD. This implies a price increase of 17.47% is expected in the next year compared to the current price of 194.2.
What is the Price/Earnings (PE) ratio of JAZZ PHARMACEUTICALS PLC (JAZZ)?
The PE ratio for JAZZ PHARMACEUTICALS PLC (JAZZ) is 23.68. This is based on the reported non-GAAP earnings per share of 8.2 and the current share price of 194.2 USD.
Can you provide the upcoming earnings date for JAZZ PHARMACEUTICALS PLC?
JAZZ PHARMACEUTICALS PLC (JAZZ) will report earnings on 2026-05-04.